Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.
Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.
Oncologists have a tendency to give patients a lot of information at once regarding their diagnosis and treatment options. While it is important to give patients this information, oncologists don’t often check back with the patient to make sure they understood and remembered everything they were told, says LeBlanc.
Oncologists should be aware of how much they are talking versus how much the patient is talking and be sure to strike a balance. They should also ask the patient how they like to make decision, if they want to be actively or passively involved, and if they want a recommendation upfront or want to do their own research and come back with questions, says LeBlanc.
<<<
View more from the 2016 NCCN Hematologic Malignancies Congress
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
2 Commerce Drive
Cranbury, NJ 08512